Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission
Version of Record online: 17 NOV 2003
British Journal of Haematology
Volume 99, Issue 1, pages 64–75, October 1997
How to Cite
Engel, H., Goodacre, A., Keyhani, A., Jiang, S., Van, N. T., Kimmel, M., Sanchez-Williams, G. and Andreeff, M. (1997), Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. British Journal of Haematology, 99: 64–75. doi: 10.1046/j.1365-2141.1997.3323151.x
- Issue online: 17 NOV 2003
- Version of Record online: 17 NOV 2003
- Cited By
- minimal residual disease;
- acute myelogenous leukaemia;
- myelodysplastic syndrome;
- fluorescence in-situ hybridization;
- fluorescence activated cell sorting
The majority of patients with acute myelogenous leukaemia (AML) and myelodysplastic syndromes (MDS) relapse, especially those with unfavourable cytogenetics.
This study was designed to investigate the presence and frequency of minimal residual disease (MRD) in patients with AML or MDS (n = 35) and numerical abnormalities of chromosomes 6, 7, 8, 9, 10, 17 and 18 in clinical remission by using a combination of fluorescence activated cell sorting (FACS), fluorescence in-situ hybridization (FISH) and labelling with bromodeoxyuridine (BUdR). The technique enables the detection of as few as three leukaemic cells in 105 normal cells.
MRD was detected in 33/35 patients in complete remission (CR). 16 patients relapsed (8/11 with monosomy 7, 4/17 with trisomy 8, and 4/7 with other cytogenetic abnormalities) after a median of 4.8 months (range 3–13). Levels of MRD (P = 0.007) and proliferation index (P = 0.011) were significantly higher in patients with monosomy 7 than in patients with trisomy 8 or other cytogenetic abnormalities. The percentage of cells in S-phase, the number of abnormal cells and cytogenetic class were related to time to relapse (P = 0.001) with S-phase being the single most important prognostic factor (P = 0.0001).
We conclude that the combination of FACS/FISH/BUdR, which determines the number, phenotype and proliferation rate of very rare leukaemic cells in patients with AML or MDS in clinical remission, provides information that is useful in the identification of patients with high and low likelihood of relapse.